[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]
$orkas
Oruka Therapeutics, Inc. (ORKA) sees positive developments as the FDA clears its IND application for Phase 2a trial of ORKA-001. Analysts are reiterating Buy ratings with price targets reflecting the positive developments.
About $orkas
Oruka Therapeutics, Inc. (ORKA) is a company focused on therapeutics.
Engagements: XXX #
Engagements 24-Hour Chart Data
Current Value: XXX
Daily Average: XXX
1-Year High: XXXXX on 2025-07-23
1-Year Low: X on 2025-07-06
| Social Network | X |
|---|---|
| Engagements | XXX |
Mentions: X #
Mentions 24-Hour Chart Data
Current Value: X
Daily Average: X
1-Year High: X on 2025-07-21
1-Year Low: X on 2025-05-22
| Social Network | X |
|---|---|
| Mentions | X |
Creators: X #
Creators 24-Hour Chart Data
X unique social accounts have posts mentioning $orkas in the last XX hours which is no change from in the previous XX hours
Daily Average: X
1-Year High: X on 2025-05-22
1-Year Low: X on 2025-05-22
Top assets mentioned In the posts about $orkas in the last XX hours
Johnson & Johnson (JNJ) Oruka Therapeutics, Inc. Common Stock (ORKA) AbbVie Inc (ABBV)
Top topics mentioned In the posts about $orkas in the last XX hours
$ucbjy, $jnj, $orka, $abbv, curated
Top Social Posts #
Top posts by engagements in the last XX hours
Showing only X posts for non-authenticated requests. Use your API key in requests for full results.
"H.C. Wainwright reit'd $ORKA Buy/$45 after Oruka📰that the FDA had cleared its IND application for its Phase 2a trial of ORKA-001 (the company's long-acting anti-IL-23p19 antibody) in moderate-to-severe PsO called EVERLAST-A. $ABBV $PTGX - $JNJ #EDAV25 H.C. Wainwright said in its note: "This program is a randomized double-blind placebo-controlled Phase 2a trial designed to evaluate the safety and efficacy of a single dose level of ORKA-001 in moderate-to-severe psoriasis patients. EVERLAST-A will enroll approximately XX patients randomized 3:1 to receive ORKA-001 or matching placebo. The"
@Quantumup1 on X 2025-07-23 18:20:33 UTC 3534 followers, 1251 engagements
"Stifel reiterated $ORKA Buy-$47 after $ORKA's disclosure of the IND clearance for ORKA-001 and then catching up w/ mgmt. $ABBV $PTGX $JNJ #EADV25 $UCBJY $MLTX Stifel said in its note: "We caught up with management who noted that the IND clearance was based on interim Ph1 data (safety/tolerability) and Ph2a sites are open and actively enrolling -- Ph1 results to be presented at #EADV in September. Recall ORKA-001 is a next-gen IL-23p19 which is designed to explore greater exposure and improved dosing vs. mega-blockbuster Skyrizi based on exploratory IST results in Psoriasis demonstrating"
@Quantumup1 on X 2025-07-21 13:12:41 UTC 3534 followers, 4281 engagements